Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi

Executive Summary

PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.

You may also be interested in...



Celgene Eases Angst Over Otezla, Sets The Stage For Growth

Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.

Cancer Drugs Boost Bayer Despite Crop, Consumer and Currency Concerns

The still pending acquisition of Monsanto, crop science problems in Brazil and a weak showing from consumer health in the US cannot disguise the strong growth that Bayer's pharmaceuticals business is continuing to enjoy.

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel